Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Neuroendocrine Tumor
Interventions
DRUG

90Y-DOTA-TOC

Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.

DRUG

68Ga-DOTA-TOC

In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.

Trial Locations (1)

94158

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Thomas Hope

OTHER

NCT03197012 - Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor | Biotech Hunter | Biotech Hunter